3 Beaten-Down Genomics Stocks: Can They Recover?
Last year, the COVID-19 pandemic raised the public's appreciation for all things biology-related. It also raised a lot of biology-focused stocks.
Those gains didn't last long. This year a handful of high-profile genomics stocks that previously soared are falling along with new infection numbers.
All three of these companies can test for COVID-19, but they're well-suited to produce steadier revenue in ways that have nothing to do with coronaviruses. If you're a bargain shopper trying to figure out if these stocks are undervalued at the moment, here's what you need to know.
Source Fool.com
